BioCentury | Jan 15, 2021
Finance

Investors’ picks & access to capital in 2021: a BioCentury podcast

...of the Biogen Inc. (NASDAQ:BIIB) mAb than they had a year ago.Executive Editor Jeff Cranmer is watching Vertex Pharmaceuticals Inc....
BioCentury | Jan 12, 2021
Deals

bluebird’s split could yield two attractive M&A targets

...growing competition against its sickle cell program, among them an early stage CRISPR therapy from Vertex Pharmaceuticals Inc....
BioCentury | Jan 7, 2021
Deals

Jan. 6 Quick Takes:  Ribometrix gets $25M up front in Genentech RNA deal; plus Dewpoint-Pfizer, Kite-Oxford BioTherapeutics, Illumina-Helix and more

...commercialization. Ribometrix also has an ongoing partnership Vertex Pharmaceuticals Inc....
BioCentury | Dec 22, 2020
Deals

Dec. 21-23 Deals Quick Takes: Cytokinetics regains European rights to heart failure program; plus Boehringer-Epizyme, Vertex-Skyhawk, Lilly-Prevail, GSK-Sosei Heptares, ImmunityBio-NantKwest and more

...small molecule inhibitors of two epigenetic cancer targets in the helicase and histone acetyltransferase (HAT) families. Vertex...
...CD276)GD2 - Ganglioside GD2GPR35 – G protein-coupled receptor 35IL-15 – Interleukin-15PDE-4 - Phosphodiesterase-4 Virginia Li Skyhawk Therapeutics Inc. Vertex Pharmaceuticals Inc. Prevail...
BioCentury | Dec 12, 2020
Management Tracks

Lum & Dipp’s Biospring rounds out team; plus CHOP’s Smith-Whitley joins GBT and updates from Orphazyme, Kronos, Dewpoint, Enanta and more

...liver diseases, hired Tara Kieffer as SVP, new product strategy and development. She joins from Vertex Pharmaceuticals Inc....
BioCentury | Dec 8, 2020
Product Development

Dec. 7 ASH Quick Takes: CRISPR, Vertex update durability for edited cell therapy; plus J&J- Legend, Kura, Fate, Pfizer, Autolus and Affimed

...Assistant Editor Vertex, CRISPR update long-term data for edited cell therapyCRISPR Therapeutics AG (NASDAQ:CRSP) and Vertex Pharmaceuticals Inc....
...I Sandi Wong AFM13 AUTO3 PF-06863135 KO-539 Ciltacabtagene autoleucel (JNJ-68284528, JNJ-4528, LCAR-B38M) CTX001 Affimed N.V. Autolus Ltd. Pfizer Inc. Legend Biotech Corp. Johnson & Johnson American Society of Hematology Vertex Pharmaceuticals Inc. CRISPR...
BioCentury | Dec 8, 2020
Product Development

ASH Monday, Biden’s picks & vaccine conundrums: a BioCentury podcast

...come out?[00:04:23] Lauren Martz: The CRISPR and Vertex...
BioCentury | Dec 3, 2020
Deals

Artios picks Germany’s Merck for first major pharma collaboration in synthetic lethality

...Phase II testing. Merck obtained molecules targeting ATR and DNA-PK in a 2017 deal with Vertex Pharmaceuticals Inc....
BioCentury | Dec 1, 2020
Emerging Company Profile

Spotlight: solving CRISPR’s delivery challenges with RNPs

...therapy, NTLA-2001 from Intellia Therapeutics Inc. (NASDAQ:NTLA) and Vertex Pharmaceuticals Inc....
BioCentury | Nov 19, 2020
Finance

Nov. 18 Quick Takes: Venture rounds for Elevation, Pharvaris as Kodiak follow-on brings in $560M; plus AbCellera takes out Trianni for $90M and more

...of Tavistock Group, Janus Henderson, Samsara Biocapital and Vivo Capital and existing investors Aisling Capital, Vertex...
Items per page:
1 - 10 of 2051
BioCentury | Jan 15, 2021
Finance

Investors’ picks & access to capital in 2021: a BioCentury podcast

...of the Biogen Inc. (NASDAQ:BIIB) mAb than they had a year ago.Executive Editor Jeff Cranmer is watching Vertex Pharmaceuticals Inc....
BioCentury | Jan 12, 2021
Deals

bluebird’s split could yield two attractive M&A targets

...growing competition against its sickle cell program, among them an early stage CRISPR therapy from Vertex Pharmaceuticals Inc....
BioCentury | Jan 7, 2021
Deals

Jan. 6 Quick Takes:  Ribometrix gets $25M up front in Genentech RNA deal; plus Dewpoint-Pfizer, Kite-Oxford BioTherapeutics, Illumina-Helix and more

...commercialization. Ribometrix also has an ongoing partnership Vertex Pharmaceuticals Inc....
BioCentury | Dec 22, 2020
Deals

Dec. 21-23 Deals Quick Takes: Cytokinetics regains European rights to heart failure program; plus Boehringer-Epizyme, Vertex-Skyhawk, Lilly-Prevail, GSK-Sosei Heptares, ImmunityBio-NantKwest and more

...small molecule inhibitors of two epigenetic cancer targets in the helicase and histone acetyltransferase (HAT) families. Vertex...
...CD276)GD2 - Ganglioside GD2GPR35 – G protein-coupled receptor 35IL-15 – Interleukin-15PDE-4 - Phosphodiesterase-4 Virginia Li Skyhawk Therapeutics Inc. Vertex Pharmaceuticals Inc. Prevail...
BioCentury | Dec 12, 2020
Management Tracks

Lum & Dipp’s Biospring rounds out team; plus CHOP’s Smith-Whitley joins GBT and updates from Orphazyme, Kronos, Dewpoint, Enanta and more

...liver diseases, hired Tara Kieffer as SVP, new product strategy and development. She joins from Vertex Pharmaceuticals Inc....
BioCentury | Dec 8, 2020
Product Development

Dec. 7 ASH Quick Takes: CRISPR, Vertex update durability for edited cell therapy; plus J&J- Legend, Kura, Fate, Pfizer, Autolus and Affimed

...Assistant Editor Vertex, CRISPR update long-term data for edited cell therapyCRISPR Therapeutics AG (NASDAQ:CRSP) and Vertex Pharmaceuticals Inc....
...I Sandi Wong AFM13 AUTO3 PF-06863135 KO-539 Ciltacabtagene autoleucel (JNJ-68284528, JNJ-4528, LCAR-B38M) CTX001 Affimed N.V. Autolus Ltd. Pfizer Inc. Legend Biotech Corp. Johnson & Johnson American Society of Hematology Vertex Pharmaceuticals Inc. CRISPR...
BioCentury | Dec 8, 2020
Product Development

ASH Monday, Biden’s picks & vaccine conundrums: a BioCentury podcast

...come out?[00:04:23] Lauren Martz: The CRISPR and Vertex...
BioCentury | Dec 3, 2020
Deals

Artios picks Germany’s Merck for first major pharma collaboration in synthetic lethality

...Phase II testing. Merck obtained molecules targeting ATR and DNA-PK in a 2017 deal with Vertex Pharmaceuticals Inc....
BioCentury | Dec 1, 2020
Emerging Company Profile

Spotlight: solving CRISPR’s delivery challenges with RNPs

...therapy, NTLA-2001 from Intellia Therapeutics Inc. (NASDAQ:NTLA) and Vertex Pharmaceuticals Inc....
BioCentury | Nov 19, 2020
Finance

Nov. 18 Quick Takes: Venture rounds for Elevation, Pharvaris as Kodiak follow-on brings in $560M; plus AbCellera takes out Trianni for $90M and more

...of Tavistock Group, Janus Henderson, Samsara Biocapital and Vivo Capital and existing investors Aisling Capital, Vertex...
Items per page:
1 - 10 of 2051